Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Bevacizumab (Avastin) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy.

Next Previous
X
Search
Trial Profile

A Phase II Study of Bevacizumab (Avastin) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ADOPT

    • Most Recent Events

    • 24 Apr 2019 Status changed from recruiting to discontinued.
    • 06 Feb 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top